Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Semaglutide is a human glucagon‐like peptide‐1 analog that has been co‐formulated with the absorption enhancer, sodium N‐(8‐[2‐hydroxybenzoyl] amino) caprylate, for oral administration. This trial (NCT02016911) investigated whether hepatic impairment affects the pharmacokinetics, safety, and tolerab...

Descripción completa

Detalles Bibliográficos
Autores principales: Bækdal, Tine A., Thomsen, Mette, Kupčová, Viera, Hansen, Cilie W., Anderson, Thomas W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175428/
https://www.ncbi.nlm.nih.gov/pubmed/29693715
http://dx.doi.org/10.1002/jcph.1131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175428/
https://www.ncbi.nlm.nih.gov/pubmed/29693715
http://dx.doi.org/10.1002/jcph.1131

Ejemplares similares